Dr. Michael Zimber has over 25 years of interdisciplinary experience in the biotechnology and pharmaceutical industry with emphasis on research and discovery, preclinical development and clinical translation of medical devices and drug therapeutics. His previous industry positions include Synbiotics Corp., UniSyn Technologies, Advanced Tissue Sciences, Desmos Inc., and Acorda Therapeutics. Dr. Zimber brings his scientific expertise and strength of developing and applying innovative solutions in the laboratory to address practical scientific challenges and promote product development. He has utilized his extensive experience in early stage development of protein therapeutics, bioassay development and the generation of three-dimensional tissue constructs and bioreactor systems using various types of cells and tissues to support successful FDA submissions and approvals. Dr. Zimber is also involved with manufacturing, QA/QC, and clinical strategies and has conducted many preclinical safety and efficacy evaluations of potential therapeutics for cardiovascular, orthopedic, and dermatological indications in addition to spinal cord injury and related neurodegenerative disorders.
Dr. Zimber received his Ph.D. in neuroscience from Washington State University, and a B.S. in biological sciences from the University of Illinois at Urbana-Champaign. He is the inventor on several patents and has numerous peer-reviewed publications and is affiliated with a range of professional scientific societies where he has presented on a variety of topics in regenerative medicine, neuroscience and cell and tissue bioengineering.